Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?

Key Points

• Structure Therapeutics (NASDAQ:GPCR) shares experienced a significant gap up, opening at $21.29 after a previous close of $19.96, but last traded at $19.37.
• Recent analyst evaluations revealed new price targets, with HC Wainwright reducing their target from $75.00 to $60.00 while maintaining a "buy" rating, contributing to an average target of $75.71 among analysts.
• The company reported a loss of ($0.36) earnings per share for its latest quarterly earnings, missing the consensus estimate by ($0.08).

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $19.96, but opened at $21.29. Structure Therapeutics shares last traded at $19.37, with a volume of 166,042 shares trading hands.

Analysts Set New Price Targets

Several equities research analysts have weighed in on GPCR shares. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. Guggenheim lowered their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. JMP Securities lowered their price objective on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Citigroup assumed coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective for the company. Finally, HC Wainwright lowered their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Structure Therapeutics has a consensus rating of "Buy" and an average price target of $75.71.

Structure Therapeutics Price Performance

The company's fifty day moving average is $19.24 and its 200-day moving average is $21.09. The stock has a market cap of $1.13 billion, a PE ratio of -18.68 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08). Analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mariner LLC purchased a new position in Structure Therapeutics in the fourth quarter valued at $665,000. Barclays PLC increased its holdings in Structure Therapeutics by 42.6% in the fourth quarter. Barclays PLC now owns 115,671 shares of the company's stock valued at $3,138,000 after buying an additional 34,533 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Structure Therapeutics by 663.8% during the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company's stock worth $152,000 after purchasing an additional 7,627 shares in the last quarter. Foresite Capital Management VI LLC purchased a new stake in shares of Structure Therapeutics during the fourth quarter worth about $11,390,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Structure Therapeutics during the fourth quarter worth about $304,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.